Industry Briefs

Premium

MDS Q1 Revs Down 13 Percent, Mass Spec Unit Down 27 Percent; Renews Shareholders Rights Plan

MDS reported last week that its first-quarter revenues fell 13 percent year over year, with its MDS Analytical Technologies segment, which houses its mass spectrometry business, posting a 27 percent decline in revenues.

The firm brought in total revenues of $257 million for the three-month period ended Jan. 31. It said that excluding the impact of foreign exchange, acquisitions, and divestitures, revenues were down 1 percent compared to the year-ago period.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Two new Reproducibility Project: Cancer Biology studies have largely reproduced the original findings, ScienceInsider reports.

DNA fingerprinting could catch some sample mix-ups at pathology labs, the New York Times says.

In Cell this week: DNA methylation and T cell exhaustion, longevity in C. elegans, and more.

A Maryland police department has turned to DNA phenotyping to develop a suspect sketch, WJLA reports.